Sign in to continue:

Monday, March 2nd, 2026

HSBC Holdings plc Announces Senior Executives Share Sales – Suzanna White and Stuart Riley Transactions Disclosed

HSBC Holdings plc – Notification of Significant Share Transactions by Senior Executives

HSBC Holdings plc: Notification of Significant Share Sales by Executive Management

HSBC Holdings plc has issued an overseas regulatory announcement regarding recent transactions in its ordinary shares by two members of its senior management team. The notification is made in accordance with the UK version of the EU Market Abuse Regulation 596/2014, which is particularly relevant for shareholders and market participants monitoring insider transactions.

Key Points from the Report

  • Two senior executives, Suzanna White (Group Chief Operating Officer) and Stuart Riley (Group Chief Information Officer), have disposed of a substantial number of HSBC shares.
  • Suzanna White sold 35,000 shares in London at a price of £13.766 per share, resulting in proceeds of £481,810.00.
  • Stuart Riley sold 124,586 shares at a price of £13.762 per share, with total proceeds amounting to £1,714,552.53.
  • The transactions took place on 26 February 2026 on the London Stock Exchange (Main Market), settled in GBP.

Details of the Transactions

Suzanna White:

  • Position: Group Chief Operating Officer
  • Date of Transaction: 26 February 2026
  • Volume: 35,000 shares
  • Price: £13.77 per share
  • Total Value: £481,810.00

Stuart Riley:

  • Position: Group Chief Information Officer
  • Date of Transaction: 26 February 2026
  • Volume: 124,586 shares
  • Price: £13.76 per share
  • Total Value: £1,714,552.53

Potential Implications for Shareholders

These transactions are potentially price sensitive and warrant close attention by investors. Insider sales by senior management can sometimes be interpreted by the market as a signal regarding their outlook on the company’s future prospects, although there are many possible personal or financial reasons for such disposals. The size of the disposals, particularly Stuart Riley’s sale of over 124,000 shares, is notable and may attract scrutiny.

Investors may wish to monitor for any further disclosures or statements from HSBC or the executives regarding the rationale for these sales. While such transactions are not uncommon, the timing and scale can influence market sentiment and potentially affect share price volatility in the short term.

Shareholders should be aware that:

  • Large insider disposals can sometimes precede or coincide with key corporate developments.
  • No further information is provided in this announcement about the reasons behind the sales.
  • The Board of Directors, as listed, includes a number of independent non-executive directors, which is relevant for governance and oversight.

Contact Information for Shareholder Queries

For any questions related to these notifications, shareholders are encouraged to contact Lee Davis from Corporate Governance & Secretariat at [email protected].


Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold HSBC Holdings plc shares. The information has been compiled from regulatory disclosures and should be interpreted in the context of broader market conditions and individual investment objectives. Shareholders are advised to seek professional advice before making any investment decisions.


View HSBC HOLDINGS Historical chart here



China Aoyuan Group Announces Appointment of Receivers Over Subsidiary Properties Due to Mortgage Default

China Aoyuan Group Limited: Appointment of Receivers Over Subsidiary’s Properties China Aoyuan Group Limited: Appointment of Receivers Over Subsidiary’s Properties Key Developments Appointment of Receivers: China Aoyuan Group Limited (“the Company”) has announced the...

Duality Biotherapeutics Presents Promising Phase 1/2 Results for DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026 12

Duality Biotherapeutics Presents Positive Study Results for DB-1311/BNT324 at ASCO GU Symposium 2026 Duality Biotherapeutics Presents Positive Study Results for DB-1311/BNT324 at ASCO GU Symposium 2026 Key Highlights Updated efficacy and safety results from...

Raffles Interior Faces Audit Uncertainty Amid Integrity Issues of Executive Director Zheng Nenghuan (2025-2026)

Raffles Interior Limited – Detailed Inside Information Report Raffles Interior Limited Issues Critical Update on 2025 Annual Audit Progress Amid Integrity Concerns Surrounding Executive Director Summary Raffles Interior Limited (“the Company”, Stock Code: 1376)...

   Ad